Shaw Kevin G. 4

What Happened
Kevin G. Shaw, Senior Vice President and General Counsel of NextCure, was granted a derivative equity award on January 30, 2026 covering 8,270 shares. The Form 4 reports the acquisition as an award/grant (derivative) with a reported price of $0.00; the award is not a sale or an open-market purchase but a compensation grant.

Key Details

• Transaction date: January 30, 2026 (reported on Form 4 filed February 3, 2026) — filing appears timely under the two-business-day rule.
• Award: 8,270 derivative shares reported at $0.00 per share (classified as an award/grant).
• Shares owned after transaction: not disclosed in this filing.
• Vesting (footnote): One-fourth of the option vests on January 30, 2027; the remaining shares vest in 36 monthly installments beginning February 28, 2027.
• No 10b5-1 plan, tax-withholding, or immediate sale noted in the filing.

Context
This is a typical compensation award to an executive (an option or other derivative grant). Because the grant vests over time, it does not represent an immediate purchase or sale of stock and should be viewed as part of long-term compensation rather than an immediate market signal. The $0.00 per-share figure in the Form 4 reflects the reporting of the award itself (derivative acquisition) and not an open-market transaction.